Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, vol. 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038
Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival', Journal of Viral Hepatitis, http://dx.doi.org/10.1111/jvh.13475
Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, vol. 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
Catlett B; Bajis S; Starr M; Dore GJ; Hajarizadeh B; Cunningham PH; Applegate TL; Grebely J, 2020, 'Evaluation of the Aptima HCV Quant Dx Assay for HCV RNA detection from finger-stick capillary dried blood spot and venepuncture-collected samples.', J Infect Dis, http://dx.doi.org/10.1093/infdis/jiaa442
Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL, 2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, vol. 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, vol. 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, vol. 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101
Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B, 2020, 'Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaa612
Martinello M; Hajarizadeh B; Dore GJ, 2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, vol. 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, vol. 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2020, 'Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaa253
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, vol. 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, vol. 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598
Ferraro CF; Stewart DE; Grebely J; Tran LT; Zhou S; Puca C; Hajarizadeh B; Larney S; Santo T; Higgins JPT; Vickerman P; Degenhardt L; Hickman M; French CE, 2020, 'Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis', Addiction, http://dx.doi.org/10.1111/add.15316
Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, vol. 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
Moradi G; Hajarizadeh B; Rahmani K; Mohamadi-Bolbanabad A; Darvishi S; Zareie B; Zavareh FA; Sharafi H; Alavian SM; Ramazani R; Eftekhar M; Radfar SR; Piroozi B; Gouya MM, 2019, 'Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran', International Journal of Drug Policy, vol. 73, pp. 129 - 134, http://dx.doi.org/10.1016/j.drugpo.2019.09.018
Wallace J; Smith E; Hajarizadeh B; Richmond J; Lucke J, 2019, 'Addressing cultural diversity: the hepatitis B clinical specialist perspective', Ethnicity and Health, vol. 24, pp. 816 - 828, http://dx.doi.org/10.1080/13557858.2017.1370540
Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, vol. 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C, 2019, 'Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all', International Journal of Drug Policy, vol. 72, pp. 1 - 10, http://dx.doi.org/10.1016/j.drugpo.2019.07.016
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, vol. 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, vol. 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, vol. 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, vol. 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, vol. 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, vol. 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2
Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, vol. 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010
Major M; Gutfraind A; Shekhtman L; Cui Q; Kachko A; Cotler SJ; Hajarizadeh B; Sacks-Davis R; Page K; Boodram B; Dahari H, 2018, 'Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users', Science Translational Medicine, vol. 10, http://dx.doi.org/10.1126/scitranslmed.aao4496
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, vol. 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, vol. 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
Razavi-Shearer D; Gamkrelidze I; Nguyen MH; Chen DS; Van Damme P; Abbas Z; Abdulla M; Abou Rached A; Adda D; Aho I; Akarca U; Al Ali FH; Lawati FAL; Naamani KAL; Alashgar HI; Alavian SM; Alawadhi S; Albillos A; Al-Busafi SA; Aleman S; Alfaleh FZ; Aljumah AA; Anand AC; Anh NT; Arends JE; Arkkila P; Athanasakis K; Bane A; Ben-Ari Z; Berg T; Bizri AR; Blach S; Brandão Mello CE; Brandon SM; Bright B; Bruggmann P; Brunetto M; Buti M; Chan HLY; Chaudhry A; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Clausen MR; Colombo M; Cornberg M; Cowie B; Craxi A; Croes EA; Cuellar DA; Cunningham C; Desalegn H; Drazilova S; Duberg AS; Egeonu SS; El-Sayed MH; Estes C; Falconer K; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gaeta GB; García-Samaniego J; Genov J; Gerstoft J; Goldis A; Gountas I; Gray R; Guimarães Pessôa M; Hajarizadeh B; Hatzakis A; Hézode C; Himatt SM; Hoepelman A; Hrstic I; Hui YTT; Husa P; Jahis R; Janjua NZ; Jarcuka P; Jaroszewicz J; Kaymakoglu S; Kershenobich D; Kondili LA; Konysbekova A; Krajden M; Kristian P; Laleman W; Lao WCC; Layden J; Lazarus JV; Lee MH; Liakina V; Lim YSS; Loo CKK; Lukic B; Malekzadeh R, 2018, 'Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 383 - 403, http://dx.doi.org/10.1016/S2468-1253(18)30056-6
Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, vol. 32, pp. 269 - 279, http://dx.doi.org/10.1016/j.idc.2018.02.006
Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, vol. 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, vol. 18, http://dx.doi.org/10.1186/s12879-018-3110-0
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, vol. 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837
Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, vol. 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, vol. 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1
Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, vol. 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, vol. 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919
Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, vol. 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Cover Image', Journal of Viral Hepatitis, vol. 25, pp. i - i, http://dx.doi.org/10.1111/jvh.12604
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, vol. 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025
Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, vol. 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival Following Hospitalization With Hepatocellular Carcinoma Among People Notified With Hepatitis B or C Virus in Australia (2000-2014)', HEPATOLOGY COMMUNICATIONS, vol. 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, vol. 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020
Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, vol. 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002
Wallace J; Pitts M; Liu C; Lin V; Hajarizadeh B; Richmond J; Locarnini S, 2017, 'More than a virus: A qualitative study of the social implications of hepatitis B infection in China', International Journal for Equity in Health, vol. 16, http://dx.doi.org/10.1186/s12939-017-0637-4
Hajarizadeh B; Mesgarpour B; Nasiri MJ; Alavian SM; Merat S; Poustchi H; Malekzadeh R; Sedaghat A; Haghdoost AA, 2017, 'Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran', Hepatitis Monthly, vol. 17, http://dx.doi.org/10.5812/hepatmon.11715
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4
Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, vol. 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jarčuška P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9
Esmaeili A; Mirzazadeh A; Carter GM; Hajarizadeh B; Sacks HS; Page KA, 2017, 'Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis', Journal of Viral Hepatitis, vol. 24, pp. 117 - 127, http://dx.doi.org/10.1111/jvh.12628
Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453
Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, vol. 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, vol. 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, vol. 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025
Alavian SM; Hajarizadeh B; Lankarani KB; Sharafi H; Daryani NE; Merat S; Mohraz M; Mardani M; Fattahi MR; Poustchi H; Nikbin M; Nabavi M; Adibi P; Ziaee M; Behnava B; Rezaee-Zavareh MS; Colombo M; Massoumi H; Bizri AR; Eghtesad B; Amiri M; Namvar A; Hesamizadeh K; Malekzadeh R, 2016, 'Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.guideline
Hajarizadeh B; Razavi-Shearer D; Merat S; Alavian SM; Malekzadeh R; Razavi H, 2016, 'Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.37234
Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, vol. 16, http://dx.doi.org/10.1186/s12879-016-1567-2
Hajarizadeh B; Richmond J; Ngo N; Lucke J; Wallace J, 2016, 'Hepatitis B-related concerns and anxieties among people with chronic hepatitis B in Australia', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.35566
Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, vol. 13, http://dx.doi.org/10.1186/s12985-016-0482-x
Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, vol. 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, vol. 39, pp. 563 - 568, http://dx.doi.org/10.1111/1753-6405.12378
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, vol. 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, vol. 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384
Richmond J; Hajarizadeh B; Wallace J, 2015, 'Patients' perspectives on the delivery of hepatitis B management and care', Australian family physician, vol. 44, pp. 346
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0122232
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, http://dx.doi.org/10.1111/1753-6405.12378
Liakina V; Hamid S; Tanaka J; Olafsson S; Sharara AI; Alavian SM; Gheorghe L; El Hassan ES; Abaalkhail F; Abbas Z; Abdou A; Abourached A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alashgar HI; Alawadhi S; Al-Dabal L; Aldins P; Alfaleh FZ; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Alzaabi M; Andrea N; Assiri AM; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Blach S; Chaudhry A; Choi MS; Diab T; Djauzi S; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Goldis A; Gottfredsson M; Gregorcic S; Hajarizadeh B; Han KH; Hasan I; Hashim A; Horvath G; Hunyady B; Husni R; Jafri W; Jeruma A; Jonasson JG; Karlsdottir B; Kim DY; Kim YS; Koutoubi Z; Lesmana LA; Lim YS; Löve A; Maimets M; Makara M; Malekzadeh R; Matičič M; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Nugrahini N; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Salupere R; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Schmelzer JD; Sibley A, 2015, 'Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 4 - 20, http://dx.doi.org/10.1111/jvh.12475
Alfaleh FZ; Nugrahini N; Matičič M; Tolmane I; Alzaabi M; Hajarizadeh B; Valantinas J; Kim DY; Hunyady B; Abaalkhail F; Abbas Z; Abdou A; Abourached A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alashgar HI; Alavian SM; Alawadhi S; Al-Dabal L; Aldins P; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Andrea N; Assiri AM; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Goldis A; Gottfredsson M; Gregorcic S; Gunter J; Hamid S; Han KH; Hasan I; Hashim A; Horvath G; Husni R; Jafri W; Jeruma A; Jonasson JG; Karlsdottir B; Kim YS; Koutoubi Z; Lesmana LA; Liakina V; Lim YS; Löve A; Maimets M; Makara M; Malekzadeh R; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Salupere R; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Schmelzer JD; Sharara AI, 2015, 'Strategies to manage hepatitis C virus infection disease burden - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 42 - 65, http://dx.doi.org/10.1111/jvh.12474
Sibley A; Han KH; Abourached A; Lesmana LA; Makara M; Jafri W; Salupere R; Assiri AM; Goldis A; Abaalkhail F; Abbas Z; Abdou A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alavian SM; Alashgar HI; Alawadhi S; Al-Dabal L; Aldins P; Alfaleh FZ; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Alzaabi M; Andrea N; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Blach S; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Gottfredsson M; Gregorcic S; Gunter J; Hajarizadeh B; Hamid S; Hasan I; Hashim A; Horvath G; Hunyady B; Husni R; Jeruma A; Jonasson JG; Karlsdottir B; Kim DY; Kim YS; Koutoubi Z; Liakina V; Lim YS; Löve A; Maimets M; Malekzadeh R; Matičič M; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Nugrahini N; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Sharara AI; Siddiq M, 2015, 'The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 21 - 41, http://dx.doi.org/10.1111/jvh.12476
Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, vol. 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, vol. 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Letter: The rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C', Alimentary Pharmacology and Therapeutics, vol. 39, pp. 343, http://dx.doi.org/10.1111/apt.12589
Grebely J; Grady B; Hajarizadeh B; Page K; Dore GJ, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, vol. 59, pp. 1650 - 1651, http://dx.doi.org/10.1002/hep.26675
Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; Mcgovern BH; Schinkel J; George J; Shoukry NH; Lauer GM; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, vol. 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639
Keshvari M; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?', Liver International, vol. 34, pp. 964 - 964, http://dx.doi.org/10.1111/liv.12464
Wallace J; Hajarizadeh B; Richmond J; McNally S, 2013, 'Challenges in managing patients in Australia with chronic hepatitis B: The General Practitioners' perspective', Australian and New Zealand Journal of Public Health, vol. 37, pp. 405 - 410, http://dx.doi.org/10.1111/1753-6405.12127
Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, vol. 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107
Mirzazadeh A; Salimzadeh H; Arabi M; Hajarizadeh B; Navadeh S; Haghdoost AA, 2013, 'Trends of obesity in Iranian adults from 1990s to late 2000s; a Systematic Review and Meta-analysis', Middle East Journal of Digestive Diseases, vol. 5, pp. 151 - 157, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990178/
Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2012, 'Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia', Sexual Health, vol. 9, pp. 131 - 137, http://dx.doi.org/10.1071/SH10137
Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, vol. 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007
Wallace J; Hajarizadeh B; Richmond J; McNally S; Pitts M, 2012, 'Managing chronic hepatitis B The role of the GP', Australian Family Physician, vol. 41, pp. 893 - 898, http://search.informit.com.au/fullText;dn=896906313252806;res=IELHEA
Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2011, 'Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia', BMC Research Notes, vol. 4, http://dx.doi.org/10.1186/1756-0500-4-45
Shariat-Torbaghan S; Emami-Aleagha M; Sedighi S; Azadbakht F; Keshvari A; Hajarizadeh B; Rosai J, 2009, 'Squamous cell carcinoma arising in an ovarian mature cystic teratoma: A case report', Archives of Iranian Medicine, vol. 12, pp. 186 - 189
Alavian SM; Gooya MM; Hajarizadeh B; Esteghamati AR; Moeinzadeh AM; Haghazali M; Zamani GA; Yaghini F; Lankarani KB, 2009, 'Mass vaccination campaign against hepatitis B in adolescents in Iran: Estimating coverage using administrative data', Hepatitis Monthly, vol. 9, pp. 189 - 195
Movahedi M; Hajarizadeh B; Rahimi A; Arshinchi M; Amirhosseini K; Haghdoost AA, 2009, 'Trends and geographical inequalities of the main health indicators for rural Iran', Health Policy and Planning, vol. 24, pp. 229 - 237, http://dx.doi.org/10.1093/heapol/czp007
Alavian SM; Mohammad-Alizadeh AH; Esna-Ashari F; Ardalan G; Hajarizadeh B, 2009, 'Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures', Liver International, vol. 29, pp. 159 - 163, http://dx.doi.org/10.1111/j.1478-3231.2008.01790.x
Tavallaii SA; Mirzamani M; Heshmatzade Behzadi A; Assari S; Khoddami Vishteh HR; Hajarizadeh B; Einollahi B, 2009, 'Sexual function: A comparison between male renal transplant recipients and hemodialysis patients', Journal of Sexual Medicine, vol. 6, pp. 142 - 148, http://dx.doi.org/10.1111/j.1743-6109.2008.01047.x
Alavian SM; Hajarizadeh B; Ahmadzad-Asl M; Kabir A; Bagheri-Lankarani K, 2008, 'Hepatitis B virus infection in Iran: A systematic review', Hepatitis Monthly, vol. 8, pp. 281 - 294
Movahedi M; Haghdoost AA; Pournik O; Hajarizadeh B; Fallah MS, 2008, 'Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades', Journal of Public Health, vol. 30, pp. 499 - 504, http://dx.doi.org/10.1093/pubmed/fdn071
Sali S; Alavian SM; Hajarizadeh B, 2008, 'Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients', Nephrology, vol. 13, pp. 376 - 379, http://dx.doi.org/10.1111/j.1440-1797.2008.00952.x
Haghdoost AA; Sadeghirad B; Hajarizadeh B; Mirzazadeh A, 2007, 'The application of Systematic Review and Meta-analysis concepts in summarizing the findings of observational studies', Iranian Journal of Psychiatry, vol. 2, pp. 132 - 136, http://ijps.tums.ac.ir/index.php/ijps/article/view/453
Mirmomen S; Alavian SM; Hajarizadeh B; Kafaee J; Yektaparast B; Zahedi MJ; Zand V; Azami AA; Hosseini MMA; Faridi AR; Davari K; Hajibeigi B, 2006, 'Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: A multicenter study', Archives of Iranian Medicine, vol. 9, pp. 319 - 323
Jahani MR; Alavian SM; Shirzad H; Kabir A; Hajarizadeh B, 2005, 'Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour" [9]', Sexually Transmitted Infections, vol. 81, pp. 185, http://dx.doi.org/10.1136/sti.2004.011114
Alavian SM; Hajarizadeh B; Nematizadeh F; Larijini B, 2004, 'Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease', BMC Endocrine Disorders, vol. 4, http://dx.doi.org/10.1186/1472-6823-4-4
Alavian SM; Hajarizadeh B, 2004, 'Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs [7]', Gut, vol. 53, pp. 1057
Alavian SM; Kabir A; Hajarizadeh B; Nayebpour M; Haji Beigi B; Doroudi T; Baralle F, 2004, 'Combination Therapy of Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C', Hepatitis Monthly, vol. 4, pp. 13 - 16, http://hepatmon.portal.tools/?page=article&article_id=689
Alavian SM; Hajarizadeh B, 2004, 'Attempted suicide in two patients with chronic hepatitis C while being treated with Interferon-alpha', Hepatitis Monthly, vol. 4, pp. 20 - 22, http://hepatmon.portal.tools/?page=article&article_id=691
Alavian SM; Hajarizadeh B; Hajibeigi B; Doroudi T; Hamedianizadeh AK; Abar K, 2004, 'Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranians', Hepatitis Monthly, vol. 4, pp. 53 - 58, http://hepatmon.portal.tools/?page=article&article_id=668
Alavian SM; Einollahi B; Hajarizadeh B; Bakhtiari S; Nafar M; Ahrabi S, 2003, 'Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients', Nephrology, vol. 8, pp. 256 - 260, http://dx.doi.org/10.1046/j.1440-1797.2003.00166.x
Einollahi B; Hajarizadeh B; Bakhtiari S; Lesanpezeshki M; Khatami MR; Nourbala MH; Pourfarziani V; Alavian SM, 2003, 'Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients', Journal of Gastroenterology and Hepatology (Australia), vol. 18, pp. 836 - 840, http://dx.doi.org/10.1046/j.1440-1746.2003.03063.x
Alavian SM; Hajarizadeh B; Einollahi B, 2003, 'Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients', Transplantation Proceedings, vol. 35, pp. 2687 - 2688, http://dx.doi.org/10.1016/j.transproceed.2003.08.042
Simforoosh N; Basiri A; Pourrezagholi F; Einolahi B; Firouzan A; Moghaddam MM; Nourbala MH; Hajarizadeh B; Pourfarziani V; Lessanpezeshki M; Nafar M; Khatami MR; Moghaddam SMMH; Farhangi S, 2003, 'Is preemptive renal transplantation preferred?', Transplantation Proceedings, vol. 35, pp. 2598 - 2601, http://dx.doi.org/10.1016/j.transproceed.2003.09.026
Einollahi B; Hajarizadeh B; Simforoosh N; Lessanpezeshki M; Khatami MR; Nourbala MH; Basiri A; Pourfarziani V; Firoozan A; Nafar M; Poorrezagholi F; Sharifian M; Bakhtiari S; Alavian SM, 2003, 'Patient and graft outcome after living donor renal transplantation in Iran: More than 15-year follow-up', Transplantation Proceedings, vol. 35, pp. 2605 - 2606, http://dx.doi.org/10.1016/j.transproceed.2003.09.075
Lockart I; Hajarizadeh B; Alavi M; Davison S; Section EP; Levy MT; George J; Dore GJ; Danta M, 2020, 'Sustained virological response before hepatitis C-related hepatocellular carcinoma diagnosis is associated with improved survival', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 53 - 54, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing D; Kleman M; Cunningham P; Dore G; Applegate T; Grebely J, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Paris, FRANCE, pp. S167 - S167, presented at International Liver Congress (ILC), Paris, FRANCE, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin N; Mchutchison JG; Brainard D; Treloar C; Lloyd A; Dore G, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Paris, FRANCE, pp. S187 - S188, presented at International Liver Congress (ILC), Paris, FRANCE, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30587-7
Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore G, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, Boston, MA, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, pp. S614 - S614, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7
Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, http://dx.doi.org/10.1111/jvh.12384
Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD; Amin J; Schinkel J; Applegate TL; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 November 2014 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR; George J; Grebely J, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 November 2014 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804082&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham E; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', presented at International Liver Congress (European Association for the Study of the Liver (EASL 2018)), 11 April 2018 - 15 April 2018
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', presented at Australasian Viral Hepatitis Conference, 13 August 2018 - 15 August 2018
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', presented at Australasian Viral Hepatitis Conference (AVHC), 10 August 2017 - 11 August 2017
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S12 - S12, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30286-6
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S291 - S292, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I; Lagios K; Grebely J; Lloyd A, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S495 - S495, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31387-9
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 886A - 886A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6
Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J; Marks P; Quiene S; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Bourgeois S; Thurnheer C; Dore GJ, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3
He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, Boston, MA, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Boston, MA, 08 November 2019 - 12 November 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Hajarizadeh B; Lockart I; Alavi M; Danta M; Dore G, 2019, 'Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 71 - 72, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 April 2019 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 April 2019 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, Toronto, CANADA, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, CANADA, 14 June 2018 - 17 June 2018, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney
Hajarizadeh B, 2017, Generic direct acting antiviral treatment: The first step towards elimination of hepatitis C in Iran, http://dx.doi.org/10.5812/hepatmon.45788